Hinge Health (NYSE:HNGE) Receives Buy Rating from Needham & Company LLC

Needham & Company LLC reaffirmed their buy rating on shares of Hinge Health (NYSE:HNGE) in a research report released on Wednesday,Benzinga reports. The firm currently has a $59.00 target price on the stock.

Several other research analysts have also commented on HNGE. KeyCorp reduced their price objective on shares of Hinge Health from $72.00 to $70.00 and set an “overweight” rating for the company in a research note on Thursday, January 8th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Hinge Health in a report on Thursday, January 22nd. Stifel Nicolaus set a $59.00 price target on Hinge Health in a research report on Thursday, February 5th. Freedom Capital raised Hinge Health to a “strong-buy” rating in a research report on Thursday, January 22nd. Finally, Wells Fargo & Company began coverage on Hinge Health in a research note on Thursday, January 8th. They set an “overweight” rating and a $68.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $57.71.

Hinge Health Price Performance

HNGE opened at $38.60 on Wednesday. The firm has a market capitalization of $3.04 billion and a PE ratio of -2.94. The business’s 50-day moving average is $43.96 and its two-hundred day moving average is $48.86. Hinge Health has a 1 year low of $30.08 and a 1 year high of $62.18.

Hinge Health declared that its board has initiated a stock repurchase plan on Wednesday, November 12th that permits the company to repurchase $250.00 million in outstanding shares. This repurchase authorization permits the company to purchase up to 7.2% of its shares through open market purchases. Shares repurchase plans are often an indication that the company’s board of directors believes its shares are undervalued.

Insider Activity at Hinge Health

In other news, major shareholder Insight Holdings Group, Llc sold 1,654,440 shares of the firm’s stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $47.76, for a total value of $79,016,054.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, President James Pursley sold 15,000 shares of Hinge Health stock in a transaction dated Monday, December 22nd. The stock was sold at an average price of $48.40, for a total value of $726,000.00. Following the sale, the president directly owned 769,778 shares of the company’s stock, valued at $37,257,255.20. This trade represents a 1.91% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 2,805,105 shares of company stock worth $128,216,614 in the last quarter.

Hedge Funds Weigh In On Hinge Health

A number of institutional investors have recently bought and sold shares of the business. Lisanti Capital Growth LLC purchased a new stake in Hinge Health in the 2nd quarter worth approximately $3,089,000. JPMorgan Chase & Co. purchased a new stake in Hinge Health during the second quarter worth $43,840,000. Seven Grand Managers LLC purchased a new stake in Hinge Health during the second quarter worth $12,938,000. Foresite Capital Management VI LLC acquired a new stake in Hinge Health during the second quarter valued at $6,986,000. Finally, Strategic Blueprint LLC purchased a new position in Hinge Health in the second quarter valued at $346,000.

Hinge Health News Roundup

Here are the key news stories impacting Hinge Health this week:

• Positive Sentiment: Q4 results beat across the board — EPS and revenue topped expectations and revenue grew ~45.5% year‑over‑year, driving the rally. Earnings Report
• Positive Sentiment: Hinge raised FY2026 revenue guidance to roughly $732M–$742M (above consensus) and issued Q1 revenue guidance above estimates — a clear reason for investor optimism. Press Release
• Positive Sentiment: Company outlined a ~25% revenue growth target for 2026 and said AI-driven care investments will help scale offerings — supports the medium‑term growth story. AI & Guidance Coverage
• Positive Sentiment: Analysts remain largely constructive: Needham reaffirmed a Buy ($59 PT) and Citizens/JMP kept an Outperform with a $65 target — these notes support further upside from current levels. Analyst Notes Tickerreport
• Neutral Sentiment: Barclays trimmed its price target from $60 to $52 but kept an Overweight rating — mixed signal: still positive stance but a more conservative valuation. Barclays Note
• Neutral Sentiment: Full earnings call transcript is available for detail on margins, win rates, and cash generation — useful for confirming sustainability of trends. Earnings Transcript
• Negative Sentiment: Despite strong results, the stock trades below its 50‑ and 200‑day moving averages and carries a negative trailing P/E; if growth slows or margins disappoint, multiple compression risks exist.

About Hinge Health

Hinge Health (NYSE: HNGE) is a digital musculoskeletal (MSK) clinic that provides end-to-end solutions for the prevention and management of musculoskeletal conditions. The company’s platform combines wearable motion sensors, personalized exercise therapy guided by licensed physical therapists, and behavioral health coaching to deliver tailored treatment plans. By integrating technology with evidence-based clinical protocols, Hinge Health aims to reduce pain, improve mobility and decrease reliance on more invasive interventions such as surgery or opioid prescriptions.

Founded in 2015 and headquartered in San Francisco, Hinge Health partners with employers, health plans and other payers to offer its self-directed, app-based programs.